摘要
目的探讨晚期非小细胞肺癌患者纤维蛋白原(FIB)、D-二聚体(D-D)与表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)疗效的关系。方法回顾性分析44例EGFR敏感突变的晚期非小细胞肺癌患者的临床资料,评估FIB、D-D与疗效的关系;绘制受试者工作特征(ROC)曲线,计算二者预测TKI耐药的曲线下面积(AUC)、灵敏度、特异度。结果FIB≤498 mg/dl组、D-D≤0.55μg/ml组患者中位无进展生存时间(PFS)分别长于FIB﹥498 mg/dl组、D-D﹥0.55μg/ml组患者,差异均有统计学意义(P﹤0.05)。D-D水平与TKI耐药的一致性较高,能较好地预测TKI耐药的发生,AUC=0.83,P﹤0.01,灵敏度为87.1%,特异度为76.9%,诊断符合率为84.1%,约登指数为0.64。结论FIB、D-D对肺癌靶向治疗有较好的预测作用。
Objective To investigate the correlation between fibrinogen(FIB),D-dimer(D-D)and the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)in advanced non-small cell lung cancer(NSCLC).Method Clinical data of 44 NSCLC patients with EGFR-sensitive mutation were retrospectively analyzed.The correlation of FIB and D-D with efficacy was evaluated.Receiver operating characteristic curve(ROC)was drawn,the area under the curve(AUC),sensitivity and specificity of FIB and D-D in predicting the TKI resistance were calculated.Result The median progress-free survival(PFS)in the group with FIB≤498 mg/dl and D-D≤0.55μg/ml was longer than that with FIB>498 mg/dl and D-D>0.55μg/ml(P<0.05).There was higher consistency for the level of D-D with TKI resistance,which could precisely predict the occurrence of TKI resistance(AUC=0.83,P<0.01).The sensitivity and specificity were 87.1% and 76.9%,respectively,with coincidence rate of 84.1% and Youden index of 0.64.Conclusion FIB and D-D have good predictive value on targeted therapy of lung cancer.
作者
钱晓涛
胡格
苏杰
李蔷薇
徐秀理
QIAN Xiaotao;HU Ge;SU Jie;LI Qiangwei;XU Xiuli(Cancer Comprehensive Treatment Center,Hefei Cancer Hospital,Chinese Academy of Sciences,Hefei 230031,Anhui,China)
出处
《癌症进展》
2021年第18期1888-1891,共4页
Oncology Progress
